Candriam S.C.A. Sells 91,955 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Candriam S.C.A. cut its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 35.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 169,550 shares of the biopharmaceutical company's stock after selling 91,955 shares during the period. Candriam S.C.A. owned approximately 0.30% of Agios Pharmaceuticals worth $5,571,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Atria Investments Inc increased its stake in Agios Pharmaceuticals by 6.9% during the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after buying an additional 737 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Agios Pharmaceuticals by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 472,547 shares of the biopharmaceutical company's stock valued at $15,528,000 after buying an additional 6,927 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of Agios Pharmaceuticals by 12.3% during the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock valued at $31,567,000 after acquiring an additional 105,333 shares during the period. Bank of New York Mellon Corp grew its position in Agios Pharmaceuticals by 48.8% during the 4th quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company's stock worth $8,725,000 after purchasing an additional 87,089 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Agios Pharmaceuticals during the 4th quarter valued at $1,506,000.

Remove Ads

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Trading Down 0.5 %

Shares of Agios Pharmaceuticals stock traded down $0.15 during trading on Wednesday, hitting $31.98. 481,383 shares of the stock were exchanged, compared to its average volume of 682,048. The company has a fifty day moving average price of $33.76 and a 200-day moving average price of $42.08. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 2.82 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 1-year low of $27.14 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on AGIO shares. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target on the stock. Scotiabank boosted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Finally, StockNews.com cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.